Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition
2018
In “CFI-400945 is not a selective cellular PLK4 inhibitor,” Oegema et al. (1) raise thoughtful comments about our article (2). We appreciate their interest and critique. They propose that CFI-400945 activity was not from Polo-like kinase (PLK4) inhibition and argue that antineoplastic activity was through Aurora B kinase (1), rather than PLK4 inhibition (2).
Kinases often share related catalytic pockets, and targeting one kinase without affecting another is difficult to achieve. This is true for CFI-400945 (2) and centrinone, the PLK4 inhibitor (3) used by Oegema et al. (1). CFI-400945 is (by IC50) 38-fold more potent in causing PLK4 inhibition than in antagonizing Aurora B kinase (4, 5). Despite their claim …
[↵][1]1Email: tak.mak{at}uhnresearch.ca.
[1]: #xref-corresp-1-1
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
7
References
2
Citations
NaN
KQI